Evaluating the neonatal formulation of famotidine in a live setting

Issue

Vol. 12 No. 4 (2024): 2024 Volume -12 - Issue 4

Date Log

Published
November 23, 2024
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Evaluating the neonatal formulation of famotidine in a live setting

https://doi.org/10.61096/ijamscr.v12.iss4.2024.542-550
Golla Anjali Yadav
MNR college of Pharmacy Sangareddy, affiliated to Osmania University, Hyderabad, Telangana.
Jhancy Laxmi bai
MNR college of Pharmacy Sangareddy, affiliated to Osmania University, Hyderabad, Telangana.
V. Algarswamy
MNR college of Pharmacy Sangareddy, affiliated to Osmania University, Hyderabad, Telangana.

Corresponding Author(s) : Golla Anjali Yadav

gollaanjali11@gmail.com

International Journal of Allied Medical Sciences and Clinical Research, Vol. 12 No. 4 (2024): 2024 Volume -12 - Issue 4

Abstract

Evaluating the Neonatal Formulation of Famotidine in a Live Setting Dosage forms that can be retained in the stomach are called gastro retentive drug delivery system(GRDDS).GRDDS can improve the controlled delivery of drugs that have an absorption window by continuously releasing the drug for a prolonged period of time before it reaches its absorption site.


Oral controlled release (CR) dosage forms (DFs) have been developed over the past three decades due to their considerable therapeutic advantages such as ease of        administration, patient compliance and flexibility in formulation. However, this approach is be dilled with several physiological difficulties such as inability to restrain and locate the controlled drug delivery system within the desired region of the gastrointestinal tract (GIT) due to variable gastric emptying and motility.


Gastro retention helps to provide better availability of new products with suitable therapeutic activity and substantial benefits for patients. This mode of administration would best achieve the known pharmacokinetic and pharmacodynamic advantages of CR-DFs of these drugs.

Keywords

Evaluation Neonatal Formulation Famotidine Control release
1.
Golla Anjali Yadav, Jhancy Laxmi bai, V. Algarswamy. Evaluating the neonatal formulation of famotidine in a live setting. Int. J. of Allied Med. Sci. and Clin. Res. [Internet]. 2024 Nov. 23 [cited 2025 Jul. 11];12(4):542-50. Available from: https://ijamscr.com/ijamscr/article/view/1539
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. Rouge N, Buri P, Doelker E. Drug absorption sites in the gastrointestinal tract and dosage forms for site specific delivery. Int J Pharm. 1996; 136: 117-139.
  2. Singh BN and Kim KH. Floating drug delivery systems: an approach to oral controlled drugdelivery via gastric retention. J. Control. Release. 2000; 63: 235- 239.
  3. Streubel A, Siepmann J, Bodmeier R. Gastroretentive drug delivery system. Expert Opin Drug Deliv. 2006; 3 (2): 217-233.
  4. Ali J, Arora S, Khar RK. Floating drug delivery System: A Review. AAPS Pharm Sci Tech.2005; 06(03): E372-E390.
  5. Deshpande AA, Shah NH, Rhodes CT, Malick W. Development of a novel controlled-release system for gastric retention. Pharm Res. 1997; 14: 815-819.
  6. Davis SS, Stockwell AF, Taylor MJ. The effect of density on the gastric emptying of single and multiple unit dosage forms. Pharm Res. 1986; 3: 208-213.
  7. Lehr CM. Bioadhesion technologies for the delivery of peptide and protein drugs to thegastrointestinal tract. Crit. Rev. Ther. Drug Carrier Syst. 1994; 11: 119-160.
  8. Groning R, Heun G. Oral dosage forms with controlled gastrointestinal transit. Drug Dev IndPharm. 1984; 10: 527-539.
  9. Groning R, Heun G. Dosage forms with controlled gastrointestinal passage studies on theabsorption of nitrofurantion. Int J Pharm. 1989;56: 111-116.
  10. Klausner EA, Lavy E, Friedman M, Hoffman A. Expandable gastroretentive dosage forms. J Control Release. 2003; 90: 143 162.
  11. Vaishali sharma, Lalit Singh, Vijay Sharma, A novel approach to combat regional variability: floating drug delivery system, Volume 8, Issue 2, May – June 2011; Article-026
  12. Dave B.S, Amin A.F and Patel M.M, Gastroretentive drug delivery system of Ranitidine hydrochloride formulation and invitro evaluation, AAPS Pharm. Sci Tech (2004),5(2),1-6.
  13. Amit kumar nayak, Ruma Maji, Biswarup Das, Gastroretentive drug delivery sytems:a review, vol.3, issue 1, jan-march 2010
  14. S.S. Davis, 2005, Drug Discovery Today: Vol.10 249-256.
  15. Fix, J.A; Cargil, R; Engle, K; Gastric residence time of a non-disintegrating geometric shape in human volunteers, Pharm. Res. 1995, 12(3), 397-405.
  16. Desai, S; A floating controlled release drug delivery system; invitro/ in vivo evaluation, pharm. Res, 1993,10,1321-1325.
  17. Gupta P., Vermani K., and Grg S., hydrogels:from controlled release to PHresponsive drug delivery, drug discovery today 7(10), 2002,569-579.
  18. Babu VBM, Khar Rk, Invitro and invivo studies of sustained release floating dosage forms containing salbutamol sulphate, pharmazie,1990; 45:268-270
  19. Hetal N Kikani, A Thesis on Floating Drug Delivery System, The North Gujarat University, Patan, 2000-2001; 11-12
  20. R Garg, GD Gupta, Progress in controlled gastroretentive delivery systems, Tropical Journal of Pharmaceutical Research, September 2008; 7 (3) : 1055-1066
Read More
Author biographies is not available.
Download
PDF
Statistic
Read Counter : 46 Download : 61